Recursion Pharmaceuticals, Inc. Class A Share Price
NASDAQ: RXRX | Small CapRecursion Pharmaceuticals, Inc. Class A Stock Performance
Open $3.25 | Prev. Close $3.17 | Circuit Range N/A |
Day Range $3.19 - $3.26 | Year Range $2.77 - $7.17 | Volume 3,12,032 |
Average Traded $3.22 |
Recursion Pharmaceuticals, Inc. Class A Share Price Today
As of 10 August 2026, Recursion Pharmaceuticals, Inc. Class A's share price is $3.21. The stock opened at $3.25, compared to its previous close of $3.17. During today's trading session, Recursion Pharmaceuticals, Inc. Class A's share price traded between $3.19 and $3.26, with an average price of $3.22. Over the past 52 weeks, the stock has recorded a high of $7.17 and a low of $2.77. In terms of performance, Recursion Pharmaceuticals, Inc. Class A's share price has declined by 12.87% over the last six months and is down 31.45% on a year-on-year basis.
Recursion Pharmaceuticals, Inc. Class A Share Price Chart
Recursion Pharmaceuticals, Inc. Class A Stock Fundamentals & Key Indicators
Market Cap $1.44B | PE Ratio (TTM) -2.23 | Dividend Yield N/A |
EPS (TTM) $-1.44 | Revenue (TTM) $74.68M | Return On Equity (TTM) -57.01% |
Profit Margin -863.35% | Debt to Equity 0.13 | Quarterly Earnings Growth YoY -69.29% |
Recursion Pharmaceuticals, Inc. Class A Quarterly Profit & Loss
All figures in USD
Recursion Pharmaceuticals, Inc. Class A Annual Profit & Loss
All figures in USD
About Recursion Pharmaceuticals, Inc. Class A
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals, Inc. Class A Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $3.03 | $3.21 | +7.17% |
Jul 2026 | $3.65 | $3.00 | -18.37% |
Jun 2026 | $3.50 | $3.67 | +2.80% |
May 2026 | $3.44 | $3.58 | +3.17% |
Apr 2026 | $3.13 | $3.46 | +12.87% |
Mar 2026 | $3.46 | $3.07 | -16.80% |
Feb 2026 | $4.13 | $3.69 | -11.72% |
Jan 2026 | $4.18 | $4.18 | +2.33% |
Dec 2025 | $4.45 | $4.08 | -11.68% |
Nov 2025 | $5.56 | $4.63 | -15.91% |
Oct 2025 | $4.83 | $5.50 | +12.82% |
Sep 2025 | $4.59 | $4.88 | +3.94% |
RXRX Share Price FAQs
What is Recursion Pharmaceuticals, Inc. Class A share price today?
What is the 52 week high and 52 week low of Recursion Pharmaceuticals, Inc. Class A stock?
What is RXRX's market capitalisation today?
What is RXRX's net income for the last quarter?
What is the 5 year returns of RXRX?
What is the high & low stock price of RXRX today?
Can I buy RXRX shares in India?